PCSK9
Metabolic System · Cholesterol & Lipoprotein Metabolism
Why is PCSK9 a target of cholesterol-lowering medicines?
PCSK9 helps control how many LDL receptors are available on cells. This affects LDL clearance, but using a PCSK9-targeting medicine depends on a person's clinical lipid-management needs rather than the gene label.
- Common Gene Name
- proprotein convertase subtilisin/kexin type 9
- NCBI Gene ID
- 255738
- Chromosome
- 1
Clinical Evidence Status
Actionability report availableEstablished disease relationship
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (7 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| hypercholesterolemia, autosomal dominant, 3 | ClinGen gene-disease validity | Definitive | Autosomal dominant | View source 2018-11-14 |
| Familial hypercholesterolemia | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2020-01 | |
| Familial hypobetalipoproteinemia | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2020-01 | |
| Homozygous Familial Hypercholesterolemia | ClinGen clinical actionability | Scored report; not a validity grade | Adult | View source 2023-05-03 |
| Heterozygous Familial Hypercholesterolemia | ClinGen clinical actionability | Scored report; not a validity grade | Adult | View source 2023-06-28 |
| Heterozygous Familial Hypercholesterolemia | ClinGen clinical actionability | Scored report; not a validity grade | Pediatric | View source 2023-05-03 |
| Homozygous Familial Hypercholesterolemia | ClinGen clinical actionability | Scored report; not a validity grade | Pediatric | View source 2023-05-03 |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Metabolic System